Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weekly Erlotinib Chemoprevention in Bladder Cancer
NCT02169284Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Oct 2014
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of erlotinib in bladder carcinoma, sponsored by National Cancer Institute. Started Oct 2014; status: terminated.
02
Drugs
erlotinib
03
Conditions
bladder carcinoma
Beyond the preview
Go deeper on NCT02169284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02169284.